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OR I G I N A L A R T I C L E

Smoking cessation is associated with lower rates
of mood/anxiety and alcohol use disorders
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Background. The psychological outcomes that accompany smoking cessation are not yet conclusive but positive
outcomes could help to persuade quitting.
Method. We used data from the longitudinal National Epidemiological Study of Alcohol and Related Conditions.
Logistic regression was used to examine associations between cigarette smoking reduction and Wave 2 status of
addiction/mental health disorder among daily smokers at Wave 1, stratiﬁed by status of the diagnosis of interest at
Wave 1. We adjusted for differences in baseline covariates between smokers with different levels of smoking reduction
between Wave 1 and Wave 2 using propensity score regression adjustment.
Results. After adjusting for propensity scores and other mental health/addiction co-morbidities at Wave 2, among daily
smokers who had current or lifetime history diagnosis of the outcome of interest at Wave 1, quitting by Wave 2 predicted
a decreased risk of mood/anxiety disorder [adjusted odds ratio (aOR) 0.6, 95% conﬁdence interval (CI) 0.4–0.9] and
alcohol disorder (aOR 0.7, 95% CI 0.5–0.99) at Wave 2. Among daily smokers with no lifetime history diagnosis of
the outcome of interest at Wave 1, quitting smoking by Wave 2 predicted a decreased risk of drug use disorder at
Wave 2 (aOR 0.3, 95% CI 0.1–0.9).
Conclusions. There is no support in our data for the concern that smoking cessation would result in smokers’ increased
risk of some mental disorders. To the contrary, our data suggest that smoking cessation is associated with risk reduction
for mood/anxiety or alcohol use disorder, even among smokers who have had a pre-existing disorder.
Received 7 June 2013; Revised 25 November 2013; Accepted 7 December 2013; First published online 12 February 2014
Key words: Cessation, longitudinal data, mental health, psychiatry, smoking, substance use disorders.

Introduction
Despite substantial declines in smoking rates since the
1960s, cigarette smoking remains the leading cause
of preventable death in the USA (Adhikari et al. 2008;
Viswanath et al. 2010). From 1965 to 2011, the annual
prevalence of smoking decreased more than 50%
(Centers for Disease Control and Prevention, 2012);
however, the rates of smoking among those with psychiatric and substance use disorders remains elevated
at two to four times that of the general U.S. population
(Brown et al. 1996; Lewinsohn et al. 1999; Upadhyaya
et al. 2002; Ramsey et al. 2005; Myers & Kelly, 2006;
Tobias et al. 2008; Launiainen et al. 2011). For instance,
45% of adults with an affective disorder diagnosis and
38% with an anxiety disorder diagnosis are cigarette
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smokers versus 21% of adults without a psychiatric
diagnosis (Lawrence et al. 2009).
It is challenging to separate the role of smoking cessation in mental health functioning (Hughes, 2008).
Some research indicates that smoking cessation could
result in an increase in depressive (Borrelli et al. 1996;
Stage et al. 1996; Killen et al. 2003; Hughes, 2007) or
anxiety (West & Hajek, 1997; Becoña et al. 2002) symptoms, which in turn inﬂuences smokers’ ability or
motivation to quit (Shiffman, 1982; Covey et al. 1990;
Hall et al. 1993; Bock et al. 1996; Glassman et al. 2001;
Burgess et al. 2002). Studies vary in their reports on
the risk for developing major depressive disorder following smoking cessation, with ranges from 0% to
about 30%, with the higher rates reported among
smokers with a history of major depressive disorder
(Borrelli et al. 1996; Covey et al. 1997; Glassman et al.
2001; Killen et al. 2003; Hughes, 2007). On the contrary
and irrespective of cessation treatment, additional
studies have found that smoking cessation is seldom
associated with worsening mental health functioning
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(Leistikow & Shipley, 1999; Tsoh et al. 2000; Hall et al.
2006; Klungsoyr et al. 2006; McFall et al. 2006; Munafò
et al. 2008; Prochaska et al. 2008; Shahab & West, 2009,
2012; Hajek et al. 2010; Torres et al. 2010; Donald et al.
2013; Mathew et al. 2013). For instance, a recent study
by Morissette et al. (2012) additionally found that smokers with and without anxiety disorders and/or other
psychological disorders responded equally to high-risk
smoking triggers during the quit process with respect
to smoking urges and anxiety response; these are relevant ﬁndings given that most smokers encounter
anxiety and other mental health problems. In another
promising study, Shahab & West (2012) found that a
large majority of former smokers (69% of 879) considered themselves happier after they quit smoking.
Rates of cigarette smoking are even higher among
those with substance use disorders, with estimates up
to 80% (Kalman et al. 2005; Lawrence et al. 2009). Importantly, most people in addiction treatment want
to quit smoking (Flach & Diener, 2004) and will accept
concurrent smoking cessation treatment (Seidner et al.
1996). While a number of studies suggest that cessation
of cigarette smoking and other substances enhance
clinical outcomes (Sobell & Sobell, 1996; Stuyt, 1997;
Kohn et al. 2003; Prochaska et al. 2004a, b), smokers
with co-morbid substance use disorders do report
smoking to cope with urges to drink alcohol or use
other drugs when trying to abstain (Asher et al. 2003;
Cooney et al. 2003; Rohsenow et al. 2005; Baca &
Yahne, 2009).
Recent research indicates that smokers will lose a decade of their life but smoking cessation reduces that loss
by about 90% if it occurs before the age of 40 years (Pirie
et al. 2013). The psychological outcomes that accompany
smoking cessation are not yet conclusive; they could potentially play a role in persuading quitting behaviors if
beneﬁts exist. As a result, population-based studies
can help to reconcile the inconsistent empirical evidence
on this topic by clarifying the mental health outcomes
that are associated with smoking reduction and cessation. Our study uses two waves of data from the
National Institute on Alcohol Abuse and Alcoholism’s
(NIAAA) National Epidemiological Study of Alcohol
and Related Conditions (NESARC), allowing us to
examine the relationship between cigarette smoking reduction and cessation from Wave 1 to Wave 2 and
changes in the risk of three disorders that co-occur
highly with smoking: mood/anxiety disorders, alcohol
use disorders and drug use disorders.
Method
Data source and respondents
The analyses presented in this study utilized data from
the NESARC (Grant et al. 2004). The NESARC collected

data on the prevalence of alcohol and drug use, abuse
and dependence as well as associated psychiatric and
other medical conditions. Under contract and supervised by the NIAAA, the US Census Bureau conducted
face-to-face interviews with a multi-stage probability
sample of adults ages 18 years and older that is
nationally representative. The NESARC is a longitudinal survey consisting of Wave 1 (n = 430 93 81% response rate), conducted from 2001 to 2002, and a
3-year follow-up interview with 34 653 respondents
(Wave 2). The Wave 2 response rate was 86.7%.
Of the 8440 Wave 1 respondents who were not included in Wave 2, 3134 were not eligible for a Wave
2 interview because they were institutionalized,
mentally/physically impaired, on active duty in the
armed forces, deceased or deported. The remaining
individuals (n = 5306) were eligible but were not reinterviewed because they refused or could not be
reached or located. Wave 2 sampling weights reﬂect
design characteristics of the NESARC and account for
non-response as well as sample attrition. The weighted
Wave 2 data represent the same baseline population as
represented in Wave 1 (Ruan et al. 2008; Chen et al.
2010). The survey methods, other quality-control procedures and test–retest reliability tests have been documented in detail (Grant et al. 2003). Waves 1 and 2 of
the NESARC were used for analyses.
Only Wave 1 daily smokers who reported smoking
daily within the past year at Wave 1 and were
re-interviewed at Wave 2 were included in the analysis
(n = 6554). We excluded 1607 respondents who increased their smoking between Wave 1 and Wave 2
(i.e. average number cigarettes smoked per day increased by 510%). A total of 94 respondents with
missing data for amount of cigarettes smoked at either
Wave 1 or Wave 2 were also excluded, resulting in
4853 respondents for analysis.
A greater percentage of those with missing data,
compared with those without missing data, were
male (66.2% v. 52.2%, χ2 = 4.9, p = 0.031), and were
aged 30 years or older (87.6% v. 75.8%, χ2 = 7.1,
p = 0.010). We also multiply imputed the number of
cigarettes smoked daily at Wave 1 and Wave 2 for
those with missing data. Due to a low percentage of
respondents that had missing data and because results
from multiply imputed data were similar to complete
case analysis indicating no evidence of bias, we present
here the complete case analysis results.
Dependent variables
All NESARC interviews utilized the NIAAA’s Alcohol
Use Disorder and Associated Disabilities Interview
Schedule – DSM-IV Version (AUDADIS-IV; Grant
et al. 2003), a structured diagnostic interview with
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the list of symptom questions that assesses DSM-IV
disorders. A number of psychometric studies
have documented the reliability and validity of the
AUDADIS-IV (Grant et al. 2003). All diagnostic variables discussed below exclude symptoms due to
drugs, alcohol, or medical condition.
Status at Wave 2: current (past 12 months) mood or
anxiety disorders
A total of four Diagnostic and Statistical Manual of
Mental Disorders, fourth edition (DSM-IV) mood disorders are assessed in the NESARC: major depression,
dysthymia, mania and hypomania. The following anxiety disorders are also assessed according to DSM-IV
criteria: panic (with and without agoraphobia), agoraphobia without history of panic disorder, social phobia, speciﬁc phobia and generalized anxiety disorder.
In order to receive a formal DSM-IV diagnosis, respondents must endorse a requisite number of symptoms
pertaining to the DSM-IV criteria for a diagnosis
of interest and report the presence of social and/or occupational dysfunction associated with the disorder
(Chen et al. 2006). A participant was assigned a
mood or anxiety disorder if they met criteria in the
12 months preceding Wave 2 assessment for any of
the mood or anxiety disorders.
Status at Wave 2: current (past 12 months) DSM-IV alcohol
use disorder
A diagnosis of past 12-month DSM-IV alcohol abuse
was given to participants who met at least one of
four criteria for alcohol abuse in the year preceding
the interview, without meeting criteria for alcohol
dependence. A diagnosis of past 12-month DSM-IV
alcohol dependence was given to participants who
met at least three of seven alcohol dependence criteria
in the year preceding the interview.
Status at Wave 2: current (past 12 months) DSM-IV drug
use disorder
The DSM-IV drug use disorder diagnoses assessed
in the NESARC include the following drug groups:
sedatives, tranquilizers, opiates (other than heroin or
methadone), amphetamines, cannabis, hallucinogens,
cocaine (including crack cocaine), inhalants/solvents,
heroin, or other drugs. For a drug-speciﬁc abuse diagnosis, at least one of the four abuse criteria is required.
To meet a drug-speciﬁc dependence diagnosis, at least
three of the seven dependence criteria are required
(diagnoses for cannabis, hallucinogen, or inhalant dependence do not use the withdrawal criterion) (Chen
et al. 2006). A participant was considered to have a diagnosis of DSM-IV drug use disorder if they met the
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abuse or dependence criteria in the past 12 months
for any of 10 drug categories.
Independent variable of interest
The primary independent variable was percentage
change in number of cigarettes per day from Wave 1
to Wave 2. All participants included in the analysis
were daily smokers at Wave 1. The number of cigarettes they smoked per day at Wave 1 was reported as
the usual quantity when they smoked. The average
number of cigarettes per day at Wave 2 was calculated
using the items assessing the usual frequency when
the respondents smoked in the past year (i.e. every
day, 5–6 days per week, 3–4 days per week, 1–2 days
per week, 2–3 days per month, once per month or
less) and the usual quantity when they smoked. The
percentage reduction in number of cigarettes per day
was calculated as the percentage change in daily smoking from Wave 1 to Wave 2. Percentage change in daily
smoking was then categorized as follows: no or minimal (1–9%) change (reference group), 10–49% reduction, 50–99% reduction, and 100% reduction.
Those who increased daily smoking by 510% were
excluded from analysis.
Statistical analysis
The percentage of daily smokers with the three outcomes of interest within the past 12 months at
Wave 2 (mood/anxiety disorder, alcohol use disorder,
drug use disorder) was examined by the amount
of reduction in daily smoking from Wave 1 to
Wave 2. These percentages, unadjusted for other variables, are presented in Figs 1–3. Analyses were stratiﬁed by history of the diagnosis of interest at Wave
1. We examined smokers with no lifetime history
(ever in lifetime up to the time of the interview) of
the speciﬁc diagnosis at Wave 1 to study the effect of
change in cigarettes per day on incident cases of the diagnosis at Wave 2. We separately analysed smokers
with current (within the past year) or lifetime history
diagnosis at Wave 1 to study the effect of change in
cigarettes per day on recurrent/persistent cases of the
diagnosis at Wave 2.
Logistic regression models were used to quantify
the association between percentage change in daily
cigarette use from Wave 1 to Wave 2 and status
of the three separate outcomes of interest at Wave 2
(Table 2). Models were stratiﬁed by status of the diagnosis of interest at Wave 1 as described above. We
ﬁrst examined the association in unadjusted bivariate
analysis. We then used propensity score methods to
adjust for potential confounding. Such methods are
used in non-randomized, observational studies to balance ‘treatment’ groups on observed covariates to

2526 P. A. Cavazos-Rehg et al.

Fig. 1. Prevalence of mood/anxiety disorder within the past 12 months at Wave 2, by smoking reduction from Wave 1 to
Wave 2, stratiﬁed by status of mood/anxiety disorder at Wave 1. Data are given as prevalence estimates (●), with lines
representing 95% conﬁdence intervals.

Fig. 2. Prevalence of alcohol abuse/dependence within the past 12 months at Wave 2, by smoking reduction from Wave 1 to
Wave 2, stratiﬁed by status of alcohol use disorder at Wave 1. Data are given as prevalence estimates (●), with lines
representing 95% conﬁdence intervals.

Smoking cessation and risk reduction in mental disorders
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Fig. 3. Prevalence of drug use disorder within the past 12 months at Wave 2, by smoking reduction from Wave 1 to Wave 2,
stratiﬁed by status of drug use disorder at Wave 1. Data are given as prevalence estimates (●), with lines representing 95%
conﬁdence intervals.

reduce bias and aid in causal inference (Rosenbaum &
Rubin, 1983). We have multiple levels of our ‘treatment’ variable [i.e. percentage reduction in smoking
between Wave 1 and Wave 2: no or minimal (1–9%)
change (reference group), 10–49% reduction, 50–99%
reduction, and 100% reduction]. Thus, we used the
multiple or ‘generalized’ propensity score as suggested
by Imbens (2000), which is the conditional probability
of receiving a particular level of the treatment given
the pre-treatment variables. Baseline (Wave 1) variables that were likely to be associated with our outcomes of interest were selected for inclusion in the
propensity score model (Brookhart et al. 2006). These
included age, sex, race/ethnicity, education, income,
marital status, employment status, private insurance,
self-perceived health, number of cigarettes smoked
daily, history of nicotine dependence, desire to quit
smoking, conduct/personality disorder, history of alcohol use disorder, frequency of drinking, heavy
drinking (i.e. 55 drinks when drank), ever sought
help for drinking, family history of alcoholism, history
of drug disorder, frequency of drug use, ever sought
help for drug use, family history of drug problems,
history of mood/anxiety disorder, norm-based mental
health scale (NBS8), how often felt downhearted/
depressed, family history of depression, and ever
sought help for mood/anxiety disorders. We also included Wave 2 survey weights as a covariate in the

propensity score model, as suggested by Zanutto
et al. (2005). The above baseline variables are similar
to those chosen in a propensity score model using
the NESARC to examine effects of drinking to selfmedicate anxiety symptoms on alcohol dependence
outcomes (Crum et al. 2013). Each of the variables
chosen was signiﬁcantly associated with at least one
of our diagnosis outcomes of interest. Because we
stratiﬁed our ﬁnal analyses by history of the diagnosis
of interest at Wave 1, we included interaction terms
for each diagnosis of interest at Wave 1 with all other
variables in the propensity score models. Due to the
difﬁculty of matching or stratifying across multiple
propensity scores (further complicated by stratifying
ﬁnal models by Wave 1 history of diagnoses), we
used the regression adjustment method (i.e. covariance
adjustment) and followed the steps outlined in
Spreeuwenberg et al. (2010).
Although our ‘treatment’ variable (levels of smoking
reduction) appears ordinal, the proportional odds
assumption was not met using ordinal logistic regression. Therefore, we used multinomial logistic regression to estimate the propensity for each level of
treatment given our observed variables listed above.
There was considerable overlap of the distributions
of the multiple propensity scores, as is recommended.
We also checked for balance of the covariates among
the four treatment groups after adjusting for three of
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the four propensity scores. Prior to adjusting for propensity scores, 23 of the covariates differed signiﬁcantly among the smoking reduction groups. After
adjusting for the multiple propensity scores (i.e. propensity for 10–49% smoking reduction, propensity for
50–99% reduction, and propensity for 100% smoking
reduction), no covariates differed signiﬁcantly among
the smoking reduction groups. To estimate the effect
of level of smoking reduction on Wave 2 status of the
diagnoses of interest, we used logistic regression to
model the likelihood of Wave 2 diagnoses as a function
of level of smoking reduction and the three multiple
propensity scores. Then we further adjusted for Wave
2 status of the other mood/anxiety and substance use
disorders as appropriate. For example, when examining Wave 2 alcohol use disorder as an outcome, we
also included the presence of drug use disorder and
mood/anxiety disorder at Wave 2 (in past 12 months
at Wave 2 or prior to past 12 months) as covariates
in the model. Analyses were performed using SAScallable SUDAAN version 9.0.1 (RTI International,
USA), a software program that uses Taylor series linearization to adjust for design effects of complex sample
surveys like the NESARC (Shah et al. 2002). Wave 2
stratum, primary sampling units, and weights were applied to the models. Estimates in Table 2 with 95%
conﬁdence intervals (CIs) that do not include the null
value are signiﬁcant at α = 0.05.
Results
A slight majority of the daily smokers included in
the analysis was male (52.2%) and a large majority
was Caucasian (76.9%). Additional characteristics are
presented in Table 1. The average number of cigarettes
per day at Wave 1 was 18.9 (95% CI 18.5–19.3,
median = 19.3, interquartile range 9.8–19.8). Of daily
smokers, 41% underwent minimal or no change (±9%
change) in the number of cigarettes smoked daily
from Wave 1 to Wave 2, 20.1% had a 10–49% reduction
in the number of cigarettes smoked daily, 19.5% had a
50–99% reduction, and 19.2% quit smoking. The quit
rate was much higher for smokers who consumed
fewer cigarettes at Wave 1 compared with those who
consumed more cigarettes (1–5 cigarettes per day,
48.4%; 6–10 cigarettes per day, 29.0%; 11–20 cigarettes
per day, 13.7%; 21–30 cigarettes per day, 13.3%; >30
cigarettes per day, 12.0%; χ2 = 22.8, p < 0.001).
At Wave 1, 38.8% of daily smokers had history (i.e.
current or lifetime history) of mood/anxiety disorder,
50.0% had history of alcohol use disorder, and 24.2%
had history of drug use disorder. Among those with
history of the disorders at Wave 1, by Wave 2,
40.6% had recurrent/persistent mood/anxiety disorder,
25.1% had recurrent/persistent alcohol use disorder,

Table 1. Demographics of smokers who had smoked daily in the past
year at Wave 1 (n = 4853)
Variable

n (weighted %)

Sex
Female
Male

2620 (47.8)
2223 (52.2)

Race/ethnicity
Caucasian
African American
Hispanic
Asian/Native Hawaiian/Paciﬁc Islander
Native American

3173 (76.9)
857 (9.5)
604 (8.0)
82 (2.1)
137 (3.5)

Age, years
18–29
30–44
45–64
565

1060 (24.2)
1656 (34.4)
1711 (33.6)
426 (7.9)

Income
5$40 000
$15 000–$39 999
<$15 000

1912 (46.0)
1852 (36.9)
1089 (17.1)

Education
< High school
High school diploma/GED
Some college
Bachelor’s degree or more

943 (19.2)
1734 (37.1)
1572 (31.9)
604 (11.8)

Marital status
Married/living together
Not married
Divorced/widowed/separated

2214 (56.8)
1187 (22.1)
1452 (21.1)

Change in daily smoking
0 to ± 9% change
10–49% reduction
50–99% reduction
100% reduction

1912 (41.2)
994 (20.1)
986 (19.5)
961 (19.2)

GED, General Educational Development.

and 14.8% had recurrent/persistent drug use disorder.
Among the groups that did not have current or lifetime
history of the diagnosis of interest at Wave 1, 14.3%
had new onset of mood/anxiety disorder at Wave 2,
7.0% had new onset of alcohol use disorder at
Wave 2 and 2.6% had new onset of drug use disorder
at Wave 2.
Figs. 1, 2 and 3 show the percentage of respondents
with current mood/anxiety disorder, alcohol use disorder and drug use disorder at Wave 2 by change in
the number of cigarettes smoked daily from Wave 1
to Wave 2, stratiﬁed by status of the diagnosis of interest at Wave 1.
In bivariate logistic regression models (Model 1 in
Table 2), among smokers with no lifetime history of

Table 2. Associations of smoking reduction with substance use and mood/anxiety disorders at W2
Mood/anxiety disorder within past 12 months at
W2a

Model 1
(bivariate
association):
OR (95% CI)

Model 2
(adjusts for
propensity
scores): aOR
(95% CI)

Model 3d (adjusts
for propensity
scores and W2
co-morbidities):
aOR (95% CI)

Alcohol use disorder within past 12 months at W2b

Model 1
(bivariate
association):
OR (95% CI)

Model 2
(adjusts for
propensity
scores): aOR
(95% CI)

Model 1
(bivariate
association):
OR (95% CI)

Model 2
(adjusts for
propensity
scores): aOR
(95% CI)

Model 3d (adjusts
for propensity
scores and W2
co-morbidities):
aOR (95% CI)

Ref
1.3 (0.8–2.1)
0.6 (0.3–1.2)
0.8 (0.5–1.5)

Ref
0.6 (0.3–1.2)
0.5 (0.3–1.1)
0.3 (0.1–0.7)

Ref
0.6 (0.3–1.2)
0.5 (0.2–1.02)
0.3 (0.1–0.7)

Ref
0.5 (0.3–1.2)
0.5 (0.2–1.04)
0.3 (0.1–0.9)

Ref
1.1 (0.8–1.4)
0.7 (0.5–1.1)
0.7 (0.5–0.99)

Ref
1.2 (0.8–2.0)
0.8 (0.5–1.4)
0.3 (0.1–0.6)

Ref
1.1 (0.7–1.9)
0.8 (0.4–1.5)
0.3 (0.1–0.8)

Ref
1.0 (0.6–1.8)
0.9 (0.5–1.7)
0.5 (0.2–1.1)

W2, Wave 2; OR, odds ratio; CI, conﬁdence interval; aOR, adjusted odds ratio, W1, Wave 1; Ref, reference.
Mood/anxiety disorder. No lifetime history at W1: n = 2938 (448 incident cases, 2490 with no diagnosis at W2); current or lifetime history diagnosis at W1: n = 1915 (805 recurrent/
persistent cases, 1110 with no diagnosis at W2). When adjusting for propensity scores, sample sizes decreased slightly due to some missing data for included covariates. No lifetime
history at W1: n = 2845; current or lifetime history diagnosis at W1: n = 1883.
b
Alcohol use disorder. No lifetime history at W1: n = 2554 (183 incident cases, 2371 with no diagnosis at W2); current or lifetime history diagnosis at W1: n = 2299 (572 recurrent/
persistent cases, 1727 with no diagnosis at W2). When adjusting for propensity scores, sample sizes decreased slightly due to some missing data for included covariates. No lifetime
history at W1: n = 2488; current or lifetime history diagnosis at W1: n = 2240.
c
Drug use disorder. No lifetime history at W1: n = 3760 (89 incident cases, 3671 with no diagnosis at W2); current or lifetime history diagnosis at W1: n = 1093 (153 recurrent/persistent
cases, 940 with no diagnosis at W2). When adjusting for propensity scores, sample sizes decreased slightly due to some missing data for included covariates. No lifetime history at
W1: n = 3662; current or lifetime history diagnosis at W1: n = 1066.
d
Model 3 additionally adjusts for other outcome co-morbidities at W2 (e.g. the model predicting presence of alcohol use disorder at W2 adjusts for lifetime history diagnosis or past
12 months drug use disorder and mood/anxiety disorders at W2).
a
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New onset of disorder at W2 (among those with no lifetime history diagnosis at W1)
Reduction in daily smoking
0 to ±9% change
Ref
Ref
Ref
Ref
Ref
10–49% reduction
1.1 (0.8–1.6)
1.0 (0.7–1.4)
1.0 (0.7–1.4)
1.5 (0.9–2.4)
1.2 (0.7–2.0)
50–99% reduction
1.2 (0.8–1.6)
1.2 (0.8–1.6)
1.2 (0.8–1.7)
0.8 (0.5–1.4)
0.6 (0.3–1.1)
100% reduction
0.7 (0.5–1.04)
0.7 (0.5–1.1)
0.8 (0.6–1.1)
0.8 (0.5–1.3)
0.7 (0.4–1.3)
Recurrent/persistent disorder at W2 (among those with current or lifetime history diagnosis at W1)
Reduction in daily smoking
0 to ±9% change
Ref
Ref
Ref
Ref
Ref
10–49% reduction
1.2 (0.9–1.6)
1.3 (0.9–1.7)
1.3 (0.95–1.7)
1.1 (0.8–1.4)
1.1 (0.8–1.4)
50–99% reduction
0.9 (0.7–1.2)
0.9 (0.7–1.3)
0.9 (0.7–1.3)
0.7 (0.5–0.9)
0.7 (0.5–1.02)
100% reduction
0.6 (0.4–0.8)
0.6 (0.4–0.9)
0.6 (0.4–0.9)
0.6 (0.4–0.8)
0.6 (0.4–0.9)

Model 3d (adjusts
for propensity
scores and W2
co-morbidities):
aOR (95% CI)

Drug use disorder within past 12 months at W2c
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the diagnosis of interest at Wave 1, those who quit
smoking were much less likely to have new onset
of drug use disorder at Wave 2 [odds ratio (OR) 0.3,
95% CI 0.1–0.7). Quitting smoking was not signiﬁcantly associated with new onset of mood/anxiety
disorder or alcohol use disorder at Wave 2. Among
smokers with current or lifetime history diagnosis at
Wave 1, quitting smoking was associated with a decreased likelihood of recurrent/persistent mood/anxiety disorder (OR 0.6, 95% CI 0.4–0.8), alcohol use
disorder (OR 0.6, 95% CI 0.4–0.8) and drug use disorder (OR 0.3, 95% CI 0.1–0.6) at Wave 2. Reducing
daily smoking by 50–99% was also associated with a
decreased risk of recurrent/persistent alcohol use disorder at Wave 2 (OR 0.7, 95% CI 0.5–0.9).
Models adjusting for the multiple propensity
scores (i.e. propensity for 10–49%, 50–99%, and 100%
smoking reduction) and additionally for Wave 2
co-morbidities are also shown in Table 2 (models 2
and 3, respectively). Among smokers with no lifetime
history of the diagnosis of interest, there was no signiﬁcant association between reducing smoking and
new onset of mood/anxiety disorder or new onset of
alcohol use disorder at Wave 2. However, quitting
smoking was associated with a decreased risk of new
onset of drug use disorder at Wave 2 [adjusting for
propensity scores: adjusted OR (aOR) 0.3, 95% CI
0.1–0.7; further adjusting for history of alcohol and
mood disorders at Wave 2: aOR 0.3, 95% CI 0.1–0.9].
Associations were more numerous between smoking
reduction and decreased risk of recurrent/persistent
diagnoses at Wave 2, even after adjustment for propensity scores and Wave 2 co-morbidities (models 2
and 3 in Table 2). Among smokers with current or lifetime history of diagnosis of mood/anxiety disorders
at Wave 1, quitting smoking was associated with a
decreased risk of recurrent/persistent mood/anxiety
disorder at Wave 2 (adjusting for propensity scores:
aOR 0.6, 95% CI 0.4–0.9; further adjusting for history
of alcohol and drug disorders at Wave 2: aOR 0.6,
95% CI 0.4–0.9). Among smokers with current or lifetime history of diagnosis of alcohol use disorder at
Wave 1, quitting smoking was associated with a decreased risk of recurrent/persistent alcohol use disorder at Wave 2 (adjusting for propensity scores:
aOR 0.6, 95% CI 0.4–0.9; further adjusting for history
of alcohol and mood disorders at Wave 2: aOR 0.7,
95% CI 0.5–0.99). Finally, among smokers with current
or lifetime history of diagnosis of drug use disorder
at Wave 1, quitting smoking was associated with a
decreased risk of recurrent/persistent drug use disorder at Wave 2 after adjusting for propensity scores
(aOR 0.3, 95% CI 0.1–0.8), but lost signiﬁcance when
additionally adjusting for Wave 2 history of alcohol
use disorder and mood/anxiety disorder (but results

still trended in the protective direction, aOR 0.5, 95%
CI 0.2–1.1).
At Wave 1, among those with either current (within
the past 12 months) or lifetime history (prior to past
12 months) diagnosis, 64.7% had a current diagnosis
for mood/anxiety disorder, 33.7% had a current diagnosis for alcohol use disorder, and 23.0% had a current
diagnosis for drug use disorder. To examine if there
were similar associations between smoking cessation
and persistent versus recurrent cases at Wave 2, we
further stratiﬁed the ﬁnal models by those with current
diagnosis at Wave 1 (to examine persistent cases at
Wave 2) versus those with lifetime history at Wave 1
(to examine recurrent cases at Wave 2). Results showed
that the protective effects of smoking cessation on
Wave 2 status of diagnosis appeared slightly stronger
for persistent cases than recurrent cases of mood/anxiety disorder (aOR 0.5, 95% CI 0.3–0.8 and aOR 0.9, 95%
CI 0.5–1.8, respectively) and alcohol use disorder (aOR
0.5, 95% CI 0.3–0.96 and aOR 0.8, 95% CI 0.4–1.4, respectively). However, CIs were wide and still overlapping between the two groups. The effects of cessation
appeared similar for persistent and recurrent cases of
drug disorder at Wave 2 (aOR 0.4, 95% CI 0.1–1.9
and aOR 0.4, 95% CI 0.1–1.4, respectively). It should
be noted that stratifying models by current or lifetime
diagnosis further decreased sample size and thus the
power to ﬁnd statistically signiﬁcant effects. Results
are not presented for smoking reduction categories because these ﬁndings were not statistically signiﬁcant.

Discussion
We examined the effect of reducing or quitting smoking following a 3-year interval on the development of
mood/anxiety. We found that among smokers with a
prior history of a mood or anxiety disorder, smoking
cessation is associated with a lower likelihood of recurrence/persistence of mood and anxiety disorders. If we
interpret the smoking–mood/anxiety co-morbidity as
smokers ‘treating’ their mood and anxiety disorder
by smoking, our results support existing studies that
found smokers are not at increased risk of mental
health problems when they quit smoking (Leistikow
& Shipley, 1999; Tsoh et al. 2000; Hall et al. 2006;
Klungsoyr et al. 2006; McFall et al. 2006; Munafò et al.
2008; Prochaska et al. 2008; Shahab & West, 2009,
2012; Hajek et al. 2010; Torres et al. 2010; Morissette
et al. 2012; Donald et al. 2013; Mathew et al. 2013).
Additionally, we used a nationally representative sample for generalizability and the propensity score regression adjustment approach to correct for observed
differences among smokers with different levels of
smoking reduction in order to support causal
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inferences about the mental health outcomes that follow smoking reduction.
As illustrated by our Figures and ORs, mental health
status improves when smoking is reduced by 50–99%,
though statistical signiﬁcance is not quite reached.
Given the reduction of sample size that comes with
examining different levels of smoking reduction and
mental health outcomes, it may be that we are underpowered to reach statistical signiﬁcance with regards
to the psychological outcomes that accompany smoking reduction.
We also found that among smokers with pre-existing
alcohol use disorder (current or lifetime at Wave 1), a
recurrence or continuation of their alcohol use disorder
was less likely if they quit smoking by Wave 2. In addition, smokers with no history of pre-existing disorder
(for outcome of interest) who stopped smoking during
the 3 years after the initial assessment were signiﬁcantly less likely to meet criteria for a past 12-months diagnosis of drug use disorder compared with smokers
who continued to smoke the same amount; effects on
alcohol use disorder or mood and anxiety disorders
trended in the same direction but were not statistically
signiﬁcant. In other words, the risk of incident cases of
disorders known to co-occur with smoking was signiﬁcantly reduced for drug use disorders. Studies over
the last 30 years consistently agree that substance use
problems and cigarette consumption are correlated;
up to 90% of patients in substance abuse treatment settings are smokers (Anthony & Echeagaray-Wagner,
2000; Dawson, 2000; Chiolero et al. 2006). Still, the combined treatment of tobacco smoking and other addiction remains modest (Schroeder & Morris, 2010;
Guydish et al. 2011). Despite mounting scientiﬁc evidence suggesting otherwise, cessation of both substances (whether heavy alcohol or illicit drug use)
and cigarette smoking is often assumed to be too challenging (Romberger & Grant, 2004; Ziedonis et al.
2006). In contrast to this assumption, we found that
among smokers with alcohol disorders, smoking cessation is associated with a reduction in the risk of recurrence or persistence of alcohol disorder, with evidence
of no risk of relapse; ﬁndings trended near signiﬁcance
for drug use disorders. Likewise, smokers without a
prior history of drug use disorder did not have a ﬁrst
onset of drug use disorder when they quit their smoking. Previous research has similarly found that former
smokers have a higher mental and physical quality
of life than those dependent on nicotine (Miller et al.
2000; Bonard et al. 2001; Degenhardt & Hall, 2001;
Mulder et al. 2001; Hemmingsson et al. 2008). Thus,
the current study along with previous research ﬁndings bode well for smokers who quit because it is
unlikely that most smokers will spiral into drug addiction problems when they quit smoking.
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A limitation of the study is the absence of information on the timing of the events of interest during
the 3-year follow-up interval between assessments.
Therefore, it might be that some smokers stopped
drinking or using drugs (or reduced their use enough
that threshold diagnosis was no longer met) before
they quit smoking. The sequence of abstinence
before smoking cessation would corroborate past
ﬁndings that document the remission of alcohol use
disorder increases the chances of smoking cessation
(Breslau et al. 1996). Or, it may be that smoking cessation potentiates a reduction in concurrent substance
use behaviors. Importantly, our ﬁndings give further support to the notion that persons with both
alcohol or other drugs and tobacco use can quit smoking without risking an escalation of problem alcohol
and drug use.
Similarly, the direction of the relationship between smoking cessation and recurrence/persistence
of mood and anxiety disorders during the 3-year
follow-up interval is difﬁcult to disentangle. Existing
studies have indicated that the association between
cigarette smoking and psychiatric disorders is due
to shared antecedent factors (Dierker et al. 2002;
Ferguson et al. 2003; McCabe et al. 2004). Related, our
ﬁndings provide further evidence that smoking and
mental health problems are linked. Causation can go
in both directions. Speciﬁcally, persons who quit smoking may subsequently have a lower likelihood of
current depression or anxiety. Conversely, those with
remission of the co-morbid disorder may have an
easier time quitting smoking. Speciﬁcally, individuals
may have had better control of their psychiatric illness,
which in turn also spontaneously triggered smoking
cessation versus smoking cessation, prompting a remission of the psychiatric illness.
Other limitations should be mentioned. We used
propensity scores to adjust for observed differences
among smokers with different levels of smoking reduction. However, when calculating the propensity
scores we were limited to the use of variables collected
in the NESARC survey. Therefore, there could be unobserved confounders for which we could not control,
such as life-style factors that are associated with both
the likelihood of successful smoking cessation and
mental health outcomes but are not included in the
NESARC survey. However, the NESARC provides a
rich set of baseline variables and we believe that the
most important confounders are included. In addition,
we relied on participants’ self-report and our analyses
are subject to potential biases introduced by retrospective recall and accuracy of memory. There is some attrition between assessments. Moreover, it may be
that individuals under-reported recurrent cigarette
smoking and/or psychiatric symptoms because of
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multiple assessments or interviewer rapport for the
respondents that were interviewed by the same interviewer in both NESARC waves. Alternatively, we
may not have the correct time-frame to truly capture
major psychiatric illnesses which are episodic in
nature.
The considerable strengths of this study also deserve
mention. The very large sample size allowed us to
estimate incident and persistent cases of disorders of
interest separately. Each type of outcome has important scientiﬁc and public health implications. The longitudinal nature of the study, with a relatively short
follow-up interval – 3 years – allowed us to measure
change in cigarette consumption and its potential
effect on conditions that tend to co-occur with it. A
study of change in the purported independent variables in relation to the hypothesized outcomes offers
a strong epidemiological design that brings us closer
to the understanding of etiological pathways. Study
ﬁndings provide new and important epidemiological
insights into the association between smoking reduction, mental health problems, and alcohol and
drug disorders. Contrary to the widely held assumption that smoking cessation might lead to increases in
psychiatric symptoms and/or alcohol or drug use, we
found no increase and instead found a signiﬁcant decrease in risk of new cases of drug use disorder.
Among smokers with prior co-morbid disorders, quitting was associated with reduced risk for mood/anxiety disorders and alcohol disorder. Smokers have
a high prevalence of alcohol or drug use disorder
and mood/anxiety disorders (Kalman et al. 2005;
Lawrence et al. 2009); therefore, the ﬁnding that quitting smoking is associated with improved mental
health is important news. Smokers can be more compelled to quit with new knowledge that positive behavioral and psychological outcomes can accompany
smoking cessation.
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